🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Oliver on SOC in 1L DLBCL: • DA-EPOCH-R failed to improve outcomes over RCHOP • Pola-RCHOP good for ABC COO, high IPI patients, but is Hans algorithm enough? What do you think? #Lymsm Carolina Oliver #ASH24

All FDA approved CART in hematologic malignancies in a handy table. The generic names are super easy to remember.

To whom it may concern !

Check out the latest issue of Hematopoiesis - our Blood journal by trainees, for trainees. hematology.org/education/trai… ASH

1 week left to support Dana-Farber & Gronk Nation Youth Foundation! Help us finish strong + take on Rob Gronkowski in pickleball! 🎟️ $187+ = ticket to the event 🏈 $100+ = chance to win signed Gronk football 👀 Gronk, Julian Edelman , Rob Ninkovich , Patrick Chung 📅 Deadline: May 20

The Waldenström’s clinic Dana-Farber is hiring an MD! Having worked with this team for the past 6 months, I can say their advances in understanding and treating the disease are outstanding, paired with exceptional mentorship. Email: [email protected] to apply or

In a medical milestone, a customized base editor was developed, characterized in human and mouse cells, tested in mice, studied for safety in non-human primates, cleared by U.S. FDA for clinical trial use, manufactured as a complex with an LNP, and dosed into a baby with a severe,

Real-world analysis of 42,037 mNSCLC pts in the U.S 🇺🇸(2011–23): 82.1% received ≥1 biomarker test; median result time: 21 days. 🔵In 2023, EGFR and ALK had the highest testing (88.7%, 87.7%) and treatment rates (79.5%, 84.3%). Disparities persist ascopubs.org/doi/pdf/10.120…

Ph 3 randomized multicenter noninferiority trial in 234 pts with peripheral lung nodules (10–30 mm), comparing bronchoscopy to transthoracic biopsy. ⚠️Bronchoscopy was noninferior (79% vs. 73.6%) with fewer pneumothoraces (3.3% vs. 28.3%) OncoAlert 1/2 nejm.org/doi/full/10.10…

🚨Rare cancers account for 25% of all cases, yet face trial designs built for the common. Limited accrual, scarce funding, rigid endpoints—these barriers persist. But hope lies in: 🔹 Basket & adaptive designs 🔹 Tumor-agnostic therapies 🔹 N-of-1 & AI-driven trial matching 🔹

Interesting #ASCO2025 abstract: Randomized trial in NSCLC shows better ORR, PFS (13.2 vs. 6.5 mo), and OS with early (pre-15:00) vs. late immunotherapy dosing. Offers further insight into circadian effects on ICI. Also curious to see irAE impact. meetings.asco.org/abstracts-pres…

New phase 2 trial of Zanubrutinib + Ixazomib + Dexamethasone in #WaldenstromsMacroglobulinemia shows a promising VGPR+ rate (46%), but median PFS of 40 mo is only slightly better than IDR and lower than current SOC. Will depth translate to durability in time-limited combos for

We had a blast during the International Women's Media Foundation educational forum at Jacksonville, FL which coincided with our Waldenstrom Macroglobulinemia Network meeting. Our goal within the WM-NET is to address the most important clinical questions and improve the outcomes of patients with WM!

Had an amazing time at the International Waldenstrom Foundation Educational Forum, a great space to learn and connect with patients, clinicians, and researchers, all working to move the field forward. #RareDiseases IWMF Dana-Farber

Just out in NEJM! Phase 3 trial of tarlatamab, first bispecific T-cell engager (BiTE) to show activity in SCLC, demonstrates superiority over chemotherapy as 2nd-line treatment: 🔹OS: 13.6 vs. 8.3 months 🔹PFS: 4.2 vs. 3.7 months 🔹CRS: 56% (grade ≥3 only 1%) 🔹ICANS: 6%

This is impressive!

Population-based study (n=857) in adv. NSCLC showed that starting newer targeted therapies (BRAF, MET, ROS1, RET, NTRK) mainly as 1L, within 3 mo (TTI ≤3) improved OS (22 vs 14.7 mo; HR 0.69) ⚠️Delayed TTI, ECOG ≥2 & squamous histology worsened outcomes ascopubs.org/doi/10.1200/OP…

🧵 Gender Disparities in Oncology in Latin America How are female oncologists in LATAM navigating inequity, harassment, and work-life balance? A landmark study across 🇦🇷🇨🇱🇲🇽🇵🇪 sheds light on persistent gender gaps in our field published at JCO Global Oncology 🔍 Let's unpack the data